# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $205 to $200.
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $187 t...